Keywords: solvay, bifeprunox, see, peak, sales, 1b, belgium-based
Solvay's bifeprunox to see peak sales of $1B
Article | 14 June 2004
Belgium-based chemicals and pharmaceuticals firm Solvay has reassessed the commercial potential of bifeprunox, a partial dopamine agonist, currently in clinical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
